Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients—implications for therapeutic drug monitoring

Purpose To evaluate the relationship between total and free MPA pharmacokinetic (PK) parameters and renal outcome markers, and to verify whether conducting therapeutic drug monitoring (TDM) in lupus nephritis (LN) patients would be of value in routine clinical practice. Methods Eighty-four samples w...

Full description

Saved in:
Bibliographic Details
Published in:European journal of clinical pharmacology 2019-03, Vol.75 (3), p.371-379
Main Authors: Łuszczyńska, Paulina, Pawiński, Tomasz, Kunicki, Paweł K., Durlik, Magdalena, Augustyniak-Bartosik, Hanna, Hurkacz, Magdalena
Format: Article
Language:English
Subjects:
Adult
Area Under Curve
Autoimmune diseases
Biomedical and Life Sciences
Biomedicine
Concentration time
Dose-Response Relationship, Drug
Drug dosages
Drug Monitoring
Epidermal growth factor receptors
Female
Humans
Immunosuppressive Agents - administration & dosage
Immunosuppressive Agents - blood
Immunosuppressive Agents - therapeutic use
Kidney - drug effects
Kidney - metabolism
Kidney Function Tests
Lupus
Lupus nephritis
Lupus Nephritis - blood
Lupus Nephritis - drug therapy
Male
Mycophenolate mofetil
Mycophenolic acid
Mycophenolic Acid - administration & dosage
Mycophenolic Acid - blood
Mycophenolic Acid - therapeutic use
Nephritis
Pharmacokinetics
Pharmacokinetics and Disposition
Pharmacology/Toxicology
Therapeutic drug monitoring
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose To evaluate the relationship between total and free MPA pharmacokinetic (PK) parameters and renal outcome markers, and to verify whether conducting therapeutic drug monitoring (TDM) in lupus nephritis (LN) patients would be of value in routine clinical practice. Methods Eighty-four samples were collected from sixteen LN patients. Total and free MPA concentrations were measured at predose, 0.5 and 2 h after mycophenolate mofetil (MMF) intake. Area under the concentration time curve from 0 to 2 h (AUC 0–2 ) and free fraction were calculated. Results High between-patient variability was observed (CV% of 53.5% for dose-normalized total MPA AUC 0–2 ). A significant but weak correlation between dose-normalized total C 0 and AUC 0–2 was noted ( r  = 0.5699). Dose-normalized total C 0 above 2.76 μg/mL·g may indicate patients with eGFR 
ISSN:0031-6970
1432-1041
DOI:10.1007/s00228-018-2599-x